EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS).

Trial Profile

EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS).

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2010

At a glance

  • Drugs Dronedarone (Primary)
  • Indications Atrial fibrillation; Atrial flutter
  • Focus Registrational; Therapeutic Use
  • Acronyms EURIDIS
  • Sponsors Sanofi
  • Most Recent Events

    • 15 Mar 2010 Post-hoc analysis of pooled data from EURIDIS and ADONIS (in patients previously treated with amiodarone) presented at 59th Annual Scientific Session of the American College of Cardiology, according to Main Line Health media release.
    • 02 Jul 2009 The US FDA approves dronedarone [Multaq] for Patients With atrial fibrillation or atrial Flutter, according to sanofi-aventis media release.
    • 25 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top